Please login to read the full article.
Scrip Regulatory Affairs
Refining the benefit-risk framework for assessing medicines: valuing and weighting the parameters
23 February 2011
Stuart Walker, James Neil McAuslane, Lawrence Liberti
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EMA lays out drug safety priorities for 2012
- US FDA may be calling for increasingly demanding device study designs, signals draft guidance
- US FDA action on drug shortages yields results, agency improves user fee goals
- French bill tightens up on safety and conflicts of interest, but not drug approval criteria
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
